ChemoCentryx, Inc. (CCXI)
- Simply Wall St.
ChemoCentryx's (NASDAQ:CCXI) investors will be pleased with their incredible 382% return over the last five years
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
- Zacks
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
- GlobeNewswire
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g
